Document is current

Article History

Received: 28 November 2025

Accepted: 9 January 2026

First Online: 27 January 2026

Declarations

:

: The retrospective nature of the study waived the need to obtain informed consent in accordance with Finnish legislation. The study protocol was approved by the Ethical Committee of the Northern Ostrobothnia Hospital District (statement numbers 2/2015 and 115/2018). The study was conducted in compliance with the Declaration of Helsinki.

: Not applicable.

: HJ has received congress fees and travel costs from Chiesi, Mediq, and Sanofi and lecture fees from AstraZeneca outside the submitted work. JL reports congress fees and travel costs from Sanofi and GlaxoSmithKline, outside of the submitted work. RK has received lecture fees from Boehringer-Ingelheim, advisory board fees from MSD and Boehringer-Ingelheim, and congress costs from Orion Pharma outside of the submitted work. LA has received a lecture fee from Filha outside of the submitted work. The other authors declare that they have no competing interests.